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Profiles: Predicting Transplantation-Related Toxicity
and Improving Patient-Centered Outcomes
William A. Wood,1 Amy P. Abernethy,2 Sergio A. Giralt3With the advent of reduced-intensity conditioning regimens and improvements in supportive care,
hematopoietic cell transplantation (HCT) has become increasingly available to older adults and medically vul-
nerable populations with hematologic diseases. However, adverse outcomes including long-term treatment-
related distress, disability (frailty), and death remain important concerns in this population. In other areas of
oncology, comprehensive geriatric assessments have been used to stratify patients for treatment-related risk,
and patient-reported outcomes (PROs) have helped in understanding treatment-related toxicity from a pa-
tient perspective. However, these powerful tools have not yet become widely used in HCT. Here, we review
the theories and available data that support the development of pretreatment functional assessments and
longitudinal PRO sampling in HCT.We discuss the potential for these techniques to improve transplantation
outcomes through risk stratification, interventional studies, and predictive models that incorporate genetic
and biomarker data. Predicting and understanding long-term transplantation-related toxicity through func-
tional assessments and PROs will be critical to calculating the risk/benefit ratio of aggressive therapies in
older patient populations, and we contend that functional assessments and PRO sampling should become
standard parts of the routine evaluation of HCT patients.
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Over 30,000 autologous transplants and 25,000
allogeneic transplantations were performed worldwide
in 2009, representing.50% increase in allogeneic and
a.20% increase in autologous transplantation volume
over the last 10 years [1]. Improvements in supportive
care and development of reduced-intensity condition-
ing (RIC) regimens have enabled growth in transplan-
tations for patients over the age of 60 [2,3]; from 2004
to 2008, 34% of autologous transplantation recipients
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6/j.bbmt.2011.10.014older than 60, with a majority of autologous
recipients (65%) and over one-third of allogeneic
recipients older than 50 during this time period.
A substantial body of literature, mostly in the mye-
loablative setting, documents threats to health-related
quality of life (HRQOL) posed by transplantation
and related complications [4-9]. Many patients
experience significant HRQOL impairments in the
early posttransplantation period, with most reporting
that quality of life is back to baseline by 4 years
following transplantation. Nonetheless, .25% of
patients report long-term emotional distress and im-
paired life satisfaction after allogeneic transplantation
[4,5]. It is likely that these HRQOL impairments are
mediated by short- and long-term toxicities of trans-
plantation, including effects of the conditioning regi-
men, acute and chronic graft-versus-host disease
(aGVHD, cGVHD), infection, and organ dysfunction.
It is not clear whether expected long-term HRQOL
following RIC conditioning is substantially different
than after myeloablative conditioning, and in general,
the topic of HRQOL following RIC transplantation
[10,11] is relatively understudied.
There are several reasons to study long-term
HRQOL and functional impairments in older patients
conditionedwithRIC regimens. First, rates of aGVHD
and cGVHD remain significant despite RIC497
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been consistently associated with HRQOL impair-
ments [12,13]. Second, older adults are more likely to
have baseline comorbid medical illnesses [14]. Studies
using standardized transplantation comorbidity scales
have demonstrated higher treatment-related mortality
(TRM) rates in patients with higher comorbidity scores
[15], consistently so after myeloablative regimens and,
in several studies, after reduced-intensity regimens as
well [16,17]. Presumably, these findings reflect
complications of transplantation-related toxicities in
vulnerable individuals. Thus, older adults may be at
higher risk for HRQOL and functional impairments
through this mechanism.
‘‘Frailty’’ [18] is a syndrome marked by loss of
physiologic reserve, strength, and function, with an in-
creased likelihood of subsequent functional decline
and mortality. Elements that comprise the frailty syn-
drome include weight loss, exhaustion, weakness, slow
walking speed, and decreased physical activity. Outside
of hematopoietic cell transplantation (HCT), the
frailty syndrome has been associated with aging and
chronic comorbid illness. Given the expected toxicities
(aGVHD and others) of various HCT conditioning
regimens (even RIC regimens), transplantation in
older individuals carries a risk of inducing frailty; as
more older patients are undergoingHCT, the absolute
number of frail transplantation recipients are going to
increase. However, the incidence and prevalence of
frailty in transplantation survivors is understudied.
An indirect estimate of this comes from self-report of
physical functioning by HCT survivors; in one study,
22% of HCT survivors reported ongoing major phys-
ical limitations at 3 years following transplantation [8].
There is an important need withinHCT to understand
how many patients experience transplantation-related
frailty, and which patients are most at risk. A variety
of interventions have the potential to reduce incident
frailty among older people with and without cancer
such as exercise, pharmacotherapeutics, and systems
of care; studies are ongoing. Such interventions hold
similar promise for the prevention or treatment of
post-transplantation frailty.
Finally, many (although not all) studies have shown
lower TRM rates after RIC compared with myeloabla-
tive regimens. A recent large registry study demon-
strated 1-year nonrelapse mortality (NRM) rates of
25% to 35% for patients over the age of 60 who re-
ceived RIC HCT for acute myelogenous leukemia
(AML) or myelodysplastic syndromes (MDS) in first
complete remission [2]. In a retrospective institutional
review of patients over the age of 70 who received au-
tologous transplantations for lymphoma, investigators
found a 1-year NRM rate of 35% [19], substantially
higher than standard estimates of TRM for this proce-
dure. AlthoughNRM is prevalent in older patients un-
dergoing HCT and thus an important outcome topredict, only patients who survive and do not succumb
to relapse-related death will be eligible for long-term
disability and distress. In the registry study, 2-year
overall survival (OS) estimates for patients $65 with
AML and MDS were 36% and 38% respectively,
underlining the important contribution of relapse to
overall mortality. Nonetheless, the modest rates of
long-term survivorship among older HCT recipients
highlight the importance of understanding the preva-
lence of functional impairment among those who are
alive, so that we can more properly estimate the true
proportion of ‘‘excellent’’ long-term outcomes among
older adults undergoing HCT.COMPREHENSIVE GERIATRIC ASSESSMENTS
AND PATIENT-REPORTED OUTCOMES IN
CLINICAL ONCOLOGY
In other areas of oncology, measurements of phys-
iological vulnerability and patient-reported toxicity
are used routinely in research and treatment settings.
For example, a Comprehensive Geriatric Assessment
(CGA) is a frailty assessment tool used routinely in
geriatric practice that captures patient- and
physician-provided information across domains that
include functional status, comorbidity, cognitive sta-
tus, psychological state, social support, nutritional sta-
tus, and medication review [20-22]. The CGA predicts
treatment-related toxicities and OS for older individ-
uals and identifies new problems during follow-up
care, including those in cancer [23-27]. Hurria and
colleagues [28] demonstrated the feasibility of imple-
menting CGA in cancer cooperative group clinical
trials. CGAs have not yet been incorporated into
HCT-related research or practice.
Concurrently, patient-reported outcomes (PROs)
have emerged as an important way to understand and
monitor the patient experience with cancer treatment
over time. PROs are defined by the US Food and
DrugAdministration as ‘‘any report of the status of a pa-
tient’s health condition that comes directly from the pa-
tient,without interpretationof thepatient’s response by
a clinician or anyone else.’’ PROs are a reliable, valid,
and quantifiable way of monitoring symptoms, quality
of life, psychological concerns, satisfaction with care,
and treatment adherence. A classic PRO used routinely
in cancer care is the Review of Systems; there are nu-
merous validated well-recognized research instruments
(eg, FACT-G, MDASI, HADS) that can be adminis-
tered electronically or with pen and paper. Routine
PRO assessment provides a mechanism to monitor
treatment toxicity output by directly querying the pa-
tient and is more accurate than traditional clinician
symptom assessment [29,30]. PROs can also be
used to guide clinical decision making, such as
chemotherapy dosing [31], nursing interventions, and
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Many centers are now routinely collecting PRO data
as part of research protocols or routine care [33-35].
Several recent studies have shown the practical util-
ity of PRO collection in oncologic care. In a study by
Cleeland et al. [36], postsurgical patients reported
symptoms by interactive voice response technology,
and this triggered alerts to providers. The
investigators found that most clinicians responded to
the alerts, and that there was an 11% decrease in severe
symptom events in the alert group. In another study by
Berry et al. [37], clinicians were able to integrate PRO
data into their existing workflows and were more likely
to discuss issues flagged by the PRO system.
Despite the potential for longitudinal collection of
PROdata to improve routine oncologic care, commen-
tators have rightly observed that this type of data col-
lection might be better suited for nursing rather than
clinician workflow at the current time [38]. However,
as PRO data are shown to lead to measurable improve-
ments in clinical care, and as it is linked to critical issues
such as drug safety [30], this may change. When col-
lected frequently enough, PRO data have the potential
to complement laboratory assessments and clinical
exams in providing a mechanism for continuously
monitoring treatment-related toxicity, disease status
(eg, recurrence, relapse), patient functioning, and lon-
gitudinal patient experience. As these data become
more objective and reliable in appearance and function,
they are likely to become more relevant to researchers
and practicing clinicians. Despite the advances and
routine application of PRO data in clinical oncology,
however, the practice of frequent PRO sampling is still
in its very early stages in HCT.
Pretransplantation Assessments in HCT
Transplantation clinicians have generally resisted
the routine use of CGAs in part because even ‘‘older’’
transplantation recipients are still younger than the ge-
riatric population and also because of the widely held
belief that frail patients are not considered for trans-
plantation. However, individuals up to the age of 80
are now evaluated for autologous HCT, and patients
in their 70s are routinely assessed for reduced-intensity
allogeneic transplantations. Additionally, less robust
candidates are now considered for transplantation; in
one recent analysis, 81% of patients over the age of 50
met ‘‘prefrail’’ criteria and 24% met criteria for frailty,
by the 5-point Fried criteria before transplantation
[39]. In this 146 patient prospective study, frailty was
not associated with NRM, aGVHD, or OS (P 5 .32),
but higher frailty scores were associated with advanced
pre-HCT disease and higher rates of subsequent re-
lapse. These findings suggest that greater amounts of
treatment for advanced disease before HCT might
induce a frailty phenotype, and it could be theorized
that individuals with this phenotype are at higher riskfor long-term disability and distress. The lack of associ-
ation between pre-HCT frailty and other outcomes in
this study was somewhat surprising, although the use
of more nuanced measures of performance status and
the incorporation of outcomes other than death would
be worth exploring. Given the association between
frailty anddeath fromany cause, and the continued risks
for late toxicities and deaths years after transplantation,
an accurate assessment of not only pre-HCT frailty but
also post-HCT frailty is also important.
Comorbidity, a domain within the CGA, has dem-
onstrated predictive power for treatment-related tox-
icity and OS following transplantation [15]. One of
the most commonly used comorbidity scales in trans-
plantation, the hematopoietic cell transplantation-
specific comorbidity index (HCT-CI) [15], aggregates
15 different comorbidities to provide a score that can
stratify patients into lower or higher risk for NRM.
In the original Sorror study involving 1,055 consecu-
tive patients conditioned with ablative and nonablative
regimens, HCT-CI scores of 0 were associated with
2-year NRM and OS estimates of 14% and 71%, re-
spectively, whereas scores of 3 or more were associated
with 2-year NRM and OS estimates of 41% and 34%.
The HCT-CI has subsequently been found to predict
NRM and OS in different diseases, graft sources, and
conditioning regimen intensities [40-49].
There has been relatively less work in prospectively
evaluating functional status in HCT recipients beyond
standardized comorbidity assessment. One commonly
used measurement of performance status, the Karnof-
sky Performance Scale (KPS), has demonstrated utility
in predictingNRMafter transplantation [16,50]. In one
study of 408 patients receiving nonmyeloablative
allogeneic transplantations at four different centers,
investigators showed that KPS\80% was associated
with higher NRM (P 5 .04), higher incidence of $3
toxicities (P 5 .01), and higher mortality (P 5 .01). In
multivariate analysis, KPS remained associated with
mortality, but only the HCT-CI scores were still
significantly associated with NRM. In a smaller
single-institution study of 105 consecutive patients
receiving reduced-intensity conditioning with fludara-
bine, melphalan, and alemtuzumab, performance status
also influenced TRM (P 5 .03) and OS (P 5 .0056).
Separately from overall functional status, researchers
have shown differences in performance on specific
physical function tests between cancer and noncancer
patients [51], but these have not yet been evaluated or
reported prospectively as part of a pretransplantation
evaluation.
Physiologic and biologic tests measuring fitness
have the potential to enhance discriminatory power
predicting appropriateness for HCT beyond simple
measures like HCT-CI, KPS, or even global frailty
assessements. Examples include 6-minute walk test-
ing [52], DXA scanning [53], cardiopulmonary VO2
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ments beyond grip strength.Molecular tests of physio-
logic aging, such as telomere length or p16INK4a
expression levels [55]may eventually prove to have sim-
ilar utility. Combinations of these tests with standard-
ized comorbidity and performance status scoring may
allow for the construction of a routine pretransplanta-
tion assessment thatwill be as useful for transplantation
recipients as aCGA is for older individuals with cancer.
Standardized cognitive, psychologic, social, and nutri-
tional status assessments are also likely to contribute
meaningfully to the pretransplantation assessment.
Symptom Profiles in HCT
PROs [56] following HCT are influenced by
treatment-related toxicity, disease status, comorbid-
ities, psychologic functioning, and other contributors
to the overall patient experience. The term ‘‘symptom
profile’’ (or ‘‘symptom burden’’ [57]) refers to an ag-
gregate of patient-reported symptoms (eg, mucositis,
nausea, insomnia, fatigue, anxiety, depression) derived
from repetitive, daily to weekly assessments after
a physiologic stressor such as HCT. Most patients
undergoing allogeneic or autologous stem cell trans-
plantation experience multiple physical, affective,
and/or cognitive symptoms. Symptoms affect
HRQOL [6,58], and specific symptoms (such as
depression) [59] have been shown to predict eventual
morbidity and mortality after transplantation.
Symptom profiles can be expressed in several ways,
such as the number and/or severity of all or an interre-
lated subset (cluster) of symptoms, a symptom area
under the curve [60] throughout a period of time, or
symptom changes over time. The relatively new
technique of symptom profiling promises to yield
comprehensive patient-reported datasets that will be
instructive in ways that traditional, infrequent
HRQOL assessments are not. Daily to weekly symp-
tom assessments reflect underlying pathophysiology,
representing a patient-reported data stream that com-
plements clinician- and laboratory-acquired informa-
tion to monitor health. The theoretical usefulness of
this technique is at least two-fold. Increases in
patient-reported symptoms above baseline reflect an
individual’s ‘‘tolerance’’ to treatment and long-term
ability to absorb further physiologic stress. Second,
symptom assessments can help to identify changes
over time that herald the onset of clinical events.
They have both prognostic and predictive value.
To date, researchers in this area have conducted
a handful of studies in HCT that are beginning to val-
idate this approach. For example, Anderson et al. [61]
administered the MDASI-BMT to patients with
multiple myeloma (n 5 66) or non-Hodgkin lym-
phoma (n 5 34) undergoing autologous stem cell
transplantation. Patients provided symptom reports
before transplantation, at conditioning, at nadir, twicea week for 30 days thereafter, and weekly for up to
1 year. Symptoms peaked at WBC nadir, 7 to 10
days posttransplantation, and then declined to baseline
levels within several weeks. Symptom burden curves
differed by disease and by conditioning regimen. To-
gether, these observations implied that the symptom
burden was dependent on the type of physiologic
stressor (consistent with its role as a toxicity output),
and that symptom peaks corresponded with underly-
ing pathophysiology (consistent with the ability of
the symptom burden to capture changes over time).
In another autologous transplantation study, re-
searchers performed a limited longitudinal assessment
of symptoms and six cytokines during and after HCT
in 18 patients with multiple myeloma or non-
Hodgkin lymphoma, this time finding a relationship
between IL-6 and symptom severity [62].
In an allogeneic HCT symptom burden study,
Wang et al. [63] administered the MDASI to 30 pa-
tients with AML or MDS undergoing allo-HCT. As-
sessments were conducted at baseline, during
conditioning, on the day of allo-HSCT, and twice
a week for 30 days thereafter. Levels of the most severe
symptoms increased significantly from baseline to
WBC nadir and then decreased. Cytokine levels were
also sampled in the early posttransplantation period
in this study, and IL-6 and sTNFRI predicted the
intensity of the most severe early posttransplantation
symptoms. Interestingly, the nature of the symptom
burden appeared to parallel cytokine-induced ‘‘sick-
ness behavior’’ observed in mouse models. This study
again showed the feasibility of relating early posttrans-
plantation symptom changes to underlying pathophys-
iology, as measured through biomarker changes.
Finally, in a retrospective analysis of symptom
reporting in 125 allo-HCT patients, Williams et al.
[64] found that the difference in symptom burden
between patients with and without aGVHD was not
significant from the day of transplantation through
D22, but was significant between D22 and D90. This
study demonstrated the feasibility of capturing the
symptom burden farther out from transplantation
and again showed the relationship of symptoms to
changes in disease status. Unfortunately, in this study,
the symptoms were assessed too infrequently to deter-
mine whether symptoms preceded or were coincident
with aGVHD onset.
Routine PRO assessment in the HCT clinic is
straightforward, especially as electronic data capture
solutions become ubiquitous [35]. Studies in diverse
populations have found that technology-based
methods of PRO data capture are well received by
patients, if not preferred over paper-based instruments
[65,66]. A meta-analysis of 65 studies showed that
computer- and paper-administered PROs are equiva-
lent data collection methodologies, with small mean
differences that were neither statistically or clinically
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PRO collection and feedback to oncologists facilitates
physician-patient communication and has a positive
impact on HRQOL and emotional functioning [68].
When the electronic PRO system delivers a survey in-
strument that can simultaneously function as a clinical
review of systems and a validated tool for assessing
symptoms and quality of life (eg, the Patient Care
Monitor 2.0 [69]), then a unique clinical environment
is established that allows the simultaneous capture of
research-quality clinical data [35]. The PRO data can
be reported to clinicians at point of care to contribute
to in-clinic HCT patient monitoring. These data can
be subsequently linked to other datasets and analyzed
in order to understand the needs of the HCT popula-
tion, develop predictive models, and monitor quality
of care provided.
Using Pretransplantation Assessments and
SymptomProfiles to ImproveOutcomes inHCT
The techniques of pretransplantation assessment
and longitudinal symptom profiles are well positioned
to move into HCT to improve outcomes in physiolog-
ically vulnerable populations. For example, a pretrans-
plantation assessment should be developed and
validated in order to determine recipient fitness before
transplantation and distinguishing the best manage-
ment plan. In turn, the pretransplantation assessment
should then be linked with early posttransplantation
symptom profiles to identify individuals at lower or
higher risk of longer-term transplantation-related dis-
tress, disability, or death. Once these predictive
models are constructed and refined, interventions
should be developed and the impact of the interven-
tions monitored. For example, high-risk patients can
be targeted for supportive care interventions [70-75]
such as exercise or physical therapy training, health
coaching, home monitoring, or enhanced clinical
services with goals of preventing poor long-term out-
comes among older patients receiving RIC transplants.
Similarly, the primary adverse outcomes in older
transplantation recipients should be reconceptualized
to include transplantation-related frailty in addition to
transplantation-related mortality. New composite end-
points inolder transplantation recipients canbe concep-
tualized—and tested for patient-centricmeaning—such
as progression-free survival with functional indepen-
dence. Older individuals place a high priority on
functional independence as a principal determinant of
HRQOL, and relevant outcome measures are justified.
Longitudinal PROdatawill be critical to understanding
the trajectory of transplantation-related morbidity and
mortality. Profiling patient experiences in this way will
allow for comparative effectiveness studies that involve
competing treatment options of varying intensities.
Comparative effectiveness studies include not only
primary treatment outcomes (ie, survival and diseasecontrol) but also the ‘‘burden of therapy’’ borne by
patients. In addition to adverse event and cost data, lon-
gitudinal symptom profiling will add to these analyses
by including a patient-reported point of view about
the treatment experience.
Additionally, longitudinal symptom profiles in
HCT recipients must be linked to genetic and bio-
marker data to enhance mechanistic understanding of
early transplantation-related toxicity. In turn, these
models should be used to construct rational dosing
or therapeutic interventions to improve symptoms
and the overall patient experience. For example, ge-
netic polymorphisms in melphalan metabolism should
be linked to variation in symptom profiles in myeloma
patients; these data would then be used to interpret and
predict therapeutic response and toxicity at the popu-
lation and individual patient level, likely leading to
personalized modifications to melphalan dosing. As
another example, if additional symptom profile data
validate the correlation between IL-6 levels and symp-
tom peaks, then a molecule such as the anti-IL-6 anti-
body could be used to address symptoms in the early
posttransplantation period.
Symptom profiles should be linked to biomarker
data to predict risk for intermediate clinical events.
Several recent studies have looked at biomarkers pre-
dictive for or coincident with aGVHD onset; examples
of biomarkers implicated in subsequent aGVHDonset
include CRP [76], CCL8 [77], IL-6 [78,79], IL-7 [80],
IL-17 [81], and proteomic patterns [82,83]. Acute
GVHD is also associated with characteristic clinical
prodromal symptoms (malaise, anorexia, fatigue) as
well as specific symptom clusters (rash, diarrhea [84],
nausea, and others) that herald onset. Frequent symp-
tom assessments could identify changes in symptom
profiles that, when combined with biomarkers of inter-
est, might produce sufficient predictive power for
aGVHD to warrant consideration of early interven-
tion trials. Although symptom-biomarker combina-
tions are not likely to be sufficient to predict
outcome and avoid overtreatment of individuals not
destined to develop aGVHD, the morbidity and mor-
tality of delayed treatment of conditions like this might
justify this risk. If this type of symptom-biomarker
modeling proves useful for early intervention trials in
aGVHD, similar approaches might be used for other
posttransplantation complications.
The time is right for pretransplantation assessments
and longitudinal symptom profiling to be used inHCT
in much the same way that CGAs and PROs are cur-
rently being used in non-HCT settings. A growing
body of evidence demonstrates that CGAs predict
treatment-related risk and identify vulnerable popula-
tions for intervention in noncancer settings. These are
instruments already in routine use by geriatricians,
and the transplantation community would benefit
from similar application. Likewise, routine collection
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and overall improvements in the patient experience in
other cancer settings [35,85]. Because the feasibility of
this approach has been shown in HCT, longitudinal
PRO sampling is truly ready to move into usual care
for the transplantation population.
With sophistication, it is realistic to imagine com-
plex multivariable predictive models that incorporate
CGAs, longitudinal PRO data, biomarkers, and other
clinical parameters to determine individuals at risk
for near and late effects of HCT and evolving disease
recurrence, as well as signal events before they become
clinically apparent. More complex is the issue of inte-
grating these sophisticated models with individual pa-
tient data at point of care. HCT clinicians already have
a dizzying array of responsibilities, and new software
will be needed to incorporate patient level information
and support clinical decision making.
There are many reasons to support the integration
of functional assessments and symptom profiles into
HCT. We call for the routine use of these techniques
and investment in research in this area so that we can
limit treatment-related distress, disability, and death
in the patients whom we serve.ACKNOWLEDGMENTS
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